A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients
Matthew S. Davids(Dana-Farber Cancer Institute), Jennifer R. Brown(Dana-Farber Cancer Institute), Oreofe O. Odejide(Dana-Farber Cancer Institute), Josie Montegaard(Dana-Farber Cancer Institute), Philippe Armand(Harvard University), Karen Francoeur(Dana-Farber Cancer Institute), Brandon Lee(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), John Hanna(Dana-Farber Cancer Institute), Svitlana Tyekucheva(Harvard University), Mikaela M. McDonough(Dana-Farber Cancer Institute), Jon Arnason(Beth Israel Deaconess Medical Center)
Cited by 36
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890